The Economic Impact of Levothyroxine Dose Adjustments: the CONTROL HE Study
- PMID: 27798756
- PMCID: PMC5209418
- DOI: 10.1007/s40261-016-0462-3
The Economic Impact of Levothyroxine Dose Adjustments: the CONTROL HE Study
Abstract
Background: In general, hypothyroidism can be adequately treated with a consistent daily dose of levothyroxine. However, the need for levothyroxine dose adjustments is frequent in clinical practice. The extent to which levothyroxine dose adjustments increase the utilization of healthcare resources has not previously been described in the clinical literature.
Objective: The primary objective of our study was to measure the effect of levothyroxine dose adjustments in terms of their utilization of healthcare resources including direct and indirect costs. A secondary goal was to identify any differences in patient characteristics that may be responsible for levothyroxine dose adjustments.
Methods: A retrospective medical chart review was conducted among patients of selected healthcare providers in the USA. Patients who were recently started on levothyroxine therapy (<6 months) were excluded to avoid situations that were more likely attributable to treatment initiation than inadequate therapeutic effect. Trained nurses extracted data from patient charts and electronic medical record systems for review. We analyzed the cost of resources consumed by the frequency of levothyroxine dose changes over 24 months: 0 dose changes (no dose adjustment group); one dose change, two dose changes, three or more dose changes (≥1 dose adjustment group).
Results: The study included 454 patients. Overall estimated resource utilization was higher per patient in the ≥1 dose adjustment group (US$5824) vs. the no dose adjustment group (US$3166) during the 24-month study period. When direct and indirect costs were combined, overall costs of care were greatest in patients requiring three or more dose adjustments (US$8220/patient). Patients in this cohort incurred 2.5-fold greater total costs compared with patients requiring no dose adjustments (US$8220 vs. US$3166). Among the 58 patients in the group requiring three or more dose adjustments, mean direct medical costs were significantly higher than in the patients requiring no dose adjustments (US$6387 vs. US$2182). Patients with at least one dose adjustment experienced a 40.3% increase in lost productivity vs. patients who had no dose adjustments (US$1381 vs. US$984). Loss of productivity was highest among patients with three or more levothyroxine dose adjustments. Among this cohort, there was an 86.4% increase in lost productivity vs. patients who had no levothyroxine dose adjustments (US$1833 vs. US$984).
Conclusions: Patients experiencing multiple levothyroxine dose adjustments were shown to consume more healthcare resources, resulting in higher costs than those who required no dose adjustments. Each care episode contributed to lost time and wages with total estimated lost productivity escalating with increasing levothyroxine dose adjustments over a 24-month period.
Conflict of interest statement
Compliance with Ethical Standards Funding This study was funded by Akrimax Pharmaceuticals, LLC (Cranford, NJ, USA). Editorial assistance, supported by Akrimax, was provided by Aesculapius Consulting, Inc. Honoraria and consulting fees were paid by Akrimax, as detailed in the Conflict of Interest section that follows. Conflict of interest Frank Ernst, Peri Barr, and Riad Elmor are employees of Indegene, Inc., which received a fee for services related to the development and execution of this study, and for the tabulation, analysis, and reporting of its results. Walter Sandulli and Jessica Goldenberg are employees of Akrimax. Arnold Sterman has been a consultant for Akrimax, has contributed to research funded by Akrimax, and received an honorarium for his contributions to evaluating this study and to the development of this manuscript. Lionel Thevasathan has no conflicts of interest to declare. Kevin Vora was employed by Akrimax at the time of this study. Ethical standards The study protocol was reviewed and approved by Sterling Institutional Review Board, Inc., Atlanta, GA, USA. To ensure the research was in compliance with HIPAA legislation, a waiver of authorization was obtained according to 45 CFR 164.512 (i)(1)(i), which allowed the collection of protected health information without the authorization of the research participants for research purposes. Informed consent No written consent was obtained from patients (see Ethical Standards above).
Similar articles
-
The association between adherence to levothyroxine and economic and clinical outcomes in patients with hypothyroidism in the US.J Med Econ. 2018 Sep;21(9):912-919. doi: 10.1080/13696998.2018.1484749. Epub 2018 Jun 22. J Med Econ. 2018. PMID: 29865926
-
The economic impact of switching from Synthroid for the treatment of hypothyroidism.J Med Econ. 2018 May;21(5):518-524. doi: 10.1080/13696998.2018.1443110. Epub 2018 Mar 8. J Med Econ. 2018. PMID: 29458287
-
Migraine-related healthcare resource use and costs for subjects prescribed fixed-dose combination sumatriptan/naproxen sodium vs. single-entity oral triptans in a managed care population in the USA.Appl Health Econ Health Policy. 2015 Feb;13(1):109-20. doi: 10.1007/s40258-014-0129-2. Appl Health Econ Health Policy. 2015. PMID: 25294555
-
Serum thyrotropin in primary hypothyroidism. A possible predictor of optimal daily levothyroxine dose in primary hypothyroidism.Arch Intern Med. 1995 May 22;155(10):1046-8. Arch Intern Med. 1995. PMID: 7748047
-
Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.Pharmacoeconomics. 2004;22(6):389-411. doi: 10.2165/00019053-200422060-00005. Pharmacoeconomics. 2004. PMID: 15099124 Review.
Cited by
-
L-T4 Therapy in the Presence of Pharmacological Interferents.Front Endocrinol (Lausanne). 2020 Dec 22;11:607446. doi: 10.3389/fendo.2020.607446. eCollection 2020. Front Endocrinol (Lausanne). 2020. PMID: 33414765 Free PMC article. Review.
-
Levothyroxine Dose Adjustment to Optimise Therapy Throughout a Patient's Lifetime.Adv Ther. 2019 Sep;36(Suppl 2):30-46. doi: 10.1007/s12325-019-01078-2. Epub 2019 Sep 4. Adv Ther. 2019. PMID: 31485977 Free PMC article. Review.
-
Rapid supervised levothyroxine absorption test in refractory hypothyroidism: suggestion for assessing absorption using two blood samples in low-resource settings.Endocr Connect. 2024 Sep 25;13(10):e240277. doi: 10.1530/EC-24-0277. Print 2024 Oct 1. Endocr Connect. 2024. PMID: 39158596 Free PMC article.
-
ETA guidelines for the use of levothyroxine sodium preparations in monotherapy to optimize the treatment of hypothyroidism.Eur Thyroid J. 2025 Jul 31;14(4):e250123. doi: 10.1530/ETJ-25-0123. Print 2025 Aug 1. Eur Thyroid J. 2025. PMID: 40622204 Free PMC article.
-
L-T4 Therapy in Enteric Malabsorptive Disorders.Front Endocrinol (Lausanne). 2021 Feb 23;12:626371. doi: 10.3389/fendo.2021.626371. eCollection 2021. Front Endocrinol (Lausanne). 2021. PMID: 33708175 Free PMC article. Review.
References
-
- Yaturu S, Fontinot J, Rowland T. Mixed medullary thyroid cancer and follicular cancer. Am J Case Rep. 2011;12:1–4. doi: 10.12659/AJCR.881371. - DOI
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources